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Cryo-EM reveals the conformation of a substrate
analogue in the human 20S proteasome core
Paula C.A. da Fonseca1 & Edward P. Morris2
The proteasome is a highly regulated protease complex fundamental for cell homeostasis and
controlled cell cycle progression. It functions by removing a wide range of speciﬁcally tagged
proteins, including key cellular regulators. Here we present the structure of the human 20S
proteasome core bound to a substrate analogue inhibitor molecule, determined by electron
cryo-microscopy (cryo-EM) and single-particle analysis at a resolution of around 3.5Å.
Our map allows the building of protein coordinates as well as deﬁning the location and
conformation of the inhibitor at the different active sites. These results open new prospects to
tackle the proteasome functional mechanisms. Moreover, they also further demonstrate that
cryo-EM is emerging as a realistic approach for general structural studies of protein–ligand
interactions.
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T
he proteasome comprises a 20S proteolytic core that in
eukaryotes is formed from seven a and seven b subunits
arranged in pseudo-seven-fold rings, two copies of which
stack into a barrel shaped a7b7b7a7 assembly of about 750 kDa. The
proteolytic active sites correspond to the amino-terminal
(N-terminal) Thr residues of the mature b1, b2 and b5 subunits.
Each of the active sites has distinct speciﬁcities, and variants of
these are found in the interferon g induced immunoproteasome,
where the active subunits are replaced by their bi variants. Likewise,
variants are also found in cortical thymic epithelial cells, where the
bt5 thymoproteasome subunit is expressed. The crystal structure of
a 20S proteasome core was ﬁrst described for an archaeal
counterpart1 and subsequently determined for yeast2 and consti-
tutive bovine3 complexes. More recently, the crystal structures of
both constitutive and immunoproteasome 20S cores from mouse
have been reported4. These structures revealed the proteolytic sites
enclosed within an inner chamber with very restricted access.
Accordingly, the 20S core has limited proteolytic activity against
smaller peptides and unfolded proteins5, and full activation
requires the binding of regulatory complexes to the a rings at the
ends of the barrel shaped core. Such regulatory complexes include
the 19S regulatory particles, which bind to the 20S core to form the
26S proteasome and recruit fully folded protein substrates
speciﬁcally tagged for degradation by ubiquitination6.
The proteasome is a well-established target for cancer therapy
due to its critical role in the highly regulated removal of cell cycle
regulators and to its inhibition leading to apoptosis, primarily of
fast proliferating cells7. Bortezomid was the ﬁrst inhibitor of the
20S core proteolytic activity to be approved for therapeutic usage
against multiple myeloma, and a second-generation inhibitor,
carﬁlzomib, is now used in the treatment of relapsed and
refractory multiple myeloma8. In addition to the development of
better anticancer drugs, proteasome inhibitors are being explored
for other therapeutic usages including as anti-inﬂammatory and
antiviral agents. However, due to the potential cytotoxic effects
associated with 20S core inhibition, there is a great demand for
the development of inhibitors with higher speciﬁcity. X-ray
crystallography has been critical in determining the modes of
interaction of inhibitors with the 20S core and to help the rational
design of better therapeutic drugs9,10. However, these studies
require co-crystallization of protein in the presence of inhibitor or
soaking preformed protein crystals in an inhibitor containing
solution. In either case, the experimental conditions must
preserve the integrity of the protein crystals. These are not
always ideal for the protein–ligand interactions and imply ligand
binding under a non-physiological environment, where ligand
accessibility may be modulated by steric restraints imposed by
crystal contacts. With recent developments in the ﬁeld of
structural electron microscopy, including the availability of
direct electron detectors, it is now possible to determine the
structure of protein complexes by cryo-EM and single-particle
analysis at resolutions that until recently have been attained only
by crystallography or NMR11. Here we explore the use of cryo-
EM as an emerging tool for the study of protein–ligand
interactions, focusing on the structure of the human 20S
proteasome core bound to an inhibitor.
Results
Cryo-EM structure of human 20S core with an inhibitor bound.
We determined the structure of the human 20S proteasome core
bound to the inhibitor adamantaneacetyl-(6-aminohexanoyl)3-
(leucyl)3-vinylmethyl-sulfone (AdaAhx3L3VS)12 by cryo-EM and
single-particle analysis. The high quality of the ﬁnal map can be
effectively appreciated when viewed as individual sections 1Å
thick in grey-scale representation (Fig. 1a,b). Here protein density
clearly stands out against a very smooth and clean background.
Furthermore, close inspection allows immediate identiﬁcation of
the twist of a-helices (Fig. 1a) and reveals the clear separation of

























Figure 1 | Cryo-EM map of the human 20S–AdaAhx3L3VS complex. (a,b) Individual sections 1 Å thick of the 3D map, as determined by the 3D
reconstruction algorithm, are represented as grey-scale. Regions showing the pattern of a-helical secondary structure (a) and the separation of sheet
forming b strands (b) are boxed. (c) Surface representation and (d) sections of the map surface rendered and colour coded according to local resolution as
determined using ResMap15.
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displayed in this way is obtained directly from the reconstitution
algorithm, with no further ﬁltering, sharpening or masking. In
agreement with the clear recovery of structural detail in the grey-
scale sections (Fig. 1a,b), the map allows unambiguous
identiﬁcation of the protein backbone. The model of the human
20S proteasome core (Fig. 2) was built based on the crystal
structure of the mouse constitutive apo 20S core4. It reveals a
conformational rearrangement from the starting model to the ﬁnal
human 20S–AdaAhx3L3VS complex resembling that previously
described between the structure of apo and ligand bound 20S core
complexes determined by X-ray crystallography13. The ﬁnal
human 20S–AdaAhx3L3VS model was checked for geometry,
close contacts and bond parameters using MolProbity14
(Supplementary Fig. 1a). The quality of the model serves as
clear indication that during its building there is no over ﬁtting into
noise in the EM map, as this would readily lead to poor
MolProbity statistics. The resolution of the cryo-EM map can
therefore be assessed by Fourier shell correlation against a density
map generated from the coordinates of the molecular model
yielding a value of about 3.5Å (Supplementary Fig. 1b).
Furthermore, an estimate of local resolution15 assigns the
majority of the map voxels to a 3.3–3.8Å resolution range
(Fig. 1c,d and Supplementary Fig. 1c), which is consistent with the
level of detail observed (Figs 1 and 2). In agreement with the
resolution estimate, the map of the human 20S–AdaAhx3L3VS
complex shows good resolution of most side chains (Fig. 2), with a
better resolution observed in the protein interior where they are
stabilized by intraprotein contacts and steric restrains. The
reduced visibility of side chains at the protein surface appears to
be related to solvent exposure rather than distortions due to
contacts with the support carbon or with the air water interface, as
similar effects are observed for exposed residues both at the outer
surface and in the solvent ﬁlled interior cavities of the 20S core
(Figs 1c,d and 2).
Conformation of AdaAhx3L3VS at the different active sites.
AdaAhx3L3VS (Fig. 3a) is a highly potent proteasome inhibitor
that irreversibly binds all the 20S core proteolytic active sites and
can be modiﬁed to serve as a proteasome label and as a reporter
of proteasome inhibition both in vitro and in vivo12,16. The vinyl
sulfone class of 20S core inhibitors act by covalently modifying
the proteolytic active N-terminal Thr residues17. In the cryo-EM
map of the 20S–AdaAhx3L3VS complex, densities are clearly
recovered extending from the catalytically active residues of the
b1, b2 and b5 subunits (Fig. 3b–e), with no analogous densities
visible at the non-proteolytic subunits. In each case, this density is
ﬂanked by the loop between the b strands S2 and S3 and that
linking the b strand S4 and the a helix H1 of the respective active
subunit, in a similar manner to other 20S core inhibitors4,18,19.
The density extending from the N terminus of the b5 subunit can
be used to unambiguously build the L3VS moiety of the inhibitor
(Fig. 3a). Here the vinyl sulfone group and the three leucine side
chains are clearly resolved and arranged on alternate sides of the
backbone in an extended near planar conformation (Fig. 3b,c).
The remaining Ada and linker components of the inhibitor are
only partially resolved, most likely due to conformational
variability, and were therefore not modelled. The density
extending from the N terminus of the b2 subunit is also
consistent with an extended near planar conformation of the
L3VS groups (Fig. 3d). Here, however, while the densities for the
vinyl sulfone group and peptide backbone are well recovered,
only partial density is found for the leucine side chains. A similar
interpretation of the density extending from the N terminus of b1
can be made, although this is the least deﬁned of the three
inhibitor sites (Fig. 3e). Better visibility of the inhibitor densities
at the b5 active site suggests higher occupancy compared with the
b1 and b2 subunits. Accordingly, in vitro assays using puriﬁed
mammalian 20S cores revealed that AdaAhx3L3VS inhibits the




Figure 2 | Mesh representation of the map of the human 20S–AdaAhx3L3VS complex, Fourier low-pass ﬁltered to 3.4Å, with built protein
coordinates. (a) Section of the map showing the global agreement between the map densities and the coordinates of the 20S proteasome complex. Close-
up representations of an a-helix (b) and a b strand (c) are shown, illustrating substantial recovery of side-chain information.
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potency than the activities associated with the b1 and b2
subunits12.
Discussion
We present the structure determined by cryo-EM of the human
20S proteasome core bound to an inhibitor (AdaAhx3L3VS),
at a resolution of about 3.5 A´˚, in which the protein backbone
of each of its subunits is clearly identiﬁed as well as most of the
side chains. Within the structure, AdaAhx3L3VS is clearly
identiﬁed bound to each of the proteolytic sites of the 20S core.
These results can be compared with recent structures of the
archaeal apo 20S proteasome core, also determined by cryo-EM
and single-particle analysis at resolutions of 3.3 Å (ref. 20) and
2.8 Å (ref. 21). Although related, the archaeal and the eukaryotic
20S proteasome cores differ substantially in their level of
complexity. The archaeal 20S core is a D7 structure made up of
seven-fold symmetric rings of homo–heptameric a and b
subunits. The resulting 14-fold symmetry of this complex and
its stability make it a very good model protein complex to test
cryo-EM and image analysis procedures, due to the potential for
symmetry-based averaging. In contrast, the eukaryotic 20S core
has seven distinct a and b subunits. It conforms to lower C2
symmetry and, accordingly, the scope for internal averaging is
reduced by a factor of 7. Furthermore, since in the archaeal 20S
proteasome core all proteolytic active sites are identical, the
analysis of this complex offers limited scope to explore and
understand the selective targeting of the three individual
proteolytic activities of the human 20S core complex. Conse-
quently, the analysis of the archaeal complex in the presence of
inhibitors would have substantially less relevance to drug
development than the analysis of eukaryotic complexes. More
broadly, the nature of the human 20S core is much more typical
of a protein drug target, the majority of which conform to low
symmetries, making it a good example to demonstrate the
emerging potential of cryo-EM and single-particle analysis for the
study of protein–ligand interactions and for structure-based drug
design.
Structure-based drug design has been extensively used for the
development of improved 20S core inhibitors and until now these
studies involved X-ray crystallography of 20S-inhibitor com-
plexes. The closest of these inhibitors to the AdaAhx3L3VS used
here is carboxybenzyl-(leucyl)3-vinyl-sulfone (ZL3VS), which was
recently found binding only to the b5 subunit in a structure of the
yeast 20S core19. Both compounds share the proteasome active
site binding L3VS motif (Fig. 4a). By superimposing the structure
of the ZL3VS bound to the yeast 20S core onto that of the
AdaAhx3L3VS bound to the human complex, it is clear that both
share a similar binding conformation (Fig. 4b). The densities
extending from the N terminus of the b1 and b2 subunits of the
human complex also indicate an extended conformation of the
L3VS motif of the inhibitor, and their arrangement stacked within

































Figure 3 | The ligand-binding pockets at the three 20S proteasome core active sites. (a) Structural formula of the inhibitor AdaAhx3L3VS. The map of
the human 20S–AdaAhx3L3VS complex, Fourier low-pass ﬁltered to 3.4Å, is shown as a mesh (b–e). Clear densities are seen extending from the
N-terminal Thr residues of the b5 (b,c), b2 (d) and b1 (e) subunits that are consistent with the -L3VS moiety of the AdaAhx3L3VS molecule, with the vinyl
sulfone group and the side chains of the three leucine residues shown clearly resolved at the b5 site (c).
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corresponding adjacent loops (Fig. 3d,e) seems to indicate a
similar binding conformation of the L3VS motif at all three of the
20S core active sites. Furthermore, while in the yeast 20S–ZL3VS
complex ZL3VS was found binding only to the b5 subunit,
biochemical studies have shown that ZL3VS inhibits all three
proteolytic activities of the 20S core. However, a somewhat
stronger inhibition was observed for the chymotryptic activity of
the b5 subunit17. The crystals of the yeast 20S–ZL3VS complex
were obtained by soaking preformed protein crystals with an
inhibitor solution19, under conditions that must preserve the
crystals’ integrity. However, for activity studies, proteasome
samples are incubated in solution at 37 C in the presence of
inhibitor, under optimal conditions for protein–ligand
interactions17. This seems to indicate that the absence of
inhibitor at the b1 and b2 active sites in the crystal structure of
the yeast 20S–ZL3VS complex may be a consequence of the
experimental conditions used. On the other hand, in the closer to
physiological conditions used for the cryo-EM sample
preparation presented here, where the human 20S core was
incubated in solution in the presence of AdaAhx3L3VS for 1 h at
37 C, the inhibitor binds to all three of the active sites in a
manner consistent with the results obtained from the in vitro
activity studies using puriﬁed 20S core12.
Overall, our results illustrate the emerging potential of using
cryo-EM and single-particle analysis to study the protein–ligand
interactions and structure-based drug design, while opening new
opportunities for the study of detailed protein functional
mechanisms. Together with the recent report of the structure of
the Plasmodium falciparum 80S ribosome bound to an anti-
protozoan drug22, we show that cryo-EM can be used to visualize
small ligands bound to protein complexes. Moreover, the results
presented here also demonstrate the advantages of using cryo-EM
for such studies, with results consistent with activity assays, as it
allows the analysis of complexes rapidly frozen from solution and
thus under conditions closer to physiological compared with
other methods of structural determination.
Methods
Sample preparation. The human 20S proteasome core sample and AdaAhx3L3VS
were purchased from Enzo Life Sciences. The 20S proteasome core was diluted in
50mM Tris-HCl, pH 7.5, 5mM MgCl2 and 1mM dithiotreitol to a concentration
of 0.14 mM (0.1mgml 1) and incubated in the presence of 10 mM AdaAhx3L3VS
for 1 h at 37 C.
Cryo-EM. Samples were applied onto thin layers of carbon freshly ﬂoated from
mica and supported by 1.2/1.3 Quantifoil electron microscope grids. They were
then ﬂash frozen by plunging into liquid ethane using a Vitrobot (FEI), operated at
22 C and 95% humidity, with a 2.5 s blot time. During their preparation, the
grids were rendered hydrophilic by glow discharging. It was observed that the
glow discharging of the grids in air causes the 20S proteasome core to orient
predominantly with its long axis perpendicular to the support carbon. To get the
random side views required for data completeness in the three-dimensional (3D)
reconstructions, it was necessary to glow discharge the grids in the presence of
pentylamine (Supplementary Fig. 2). The grids were transferred into a FEI Titan
Krios microscope operated at an acceleration voltage of 300 keV, a nominal
magniﬁcation of  75,000 (yielding a calibrated sampling of 1.04 Å per pixel at the
image level) and a range of 1.7–3.0 mm underfocus. Images were recorded with
EPU software using a Falcon II direct electron detector, with 1 s exposure time,
giving 17 individual frames captured at a rate of 0.056 s per frame and each
corresponding to an electron dose of 2.8 e Å 2 (Supplementary Fig. 3).
Image processing. The strategy for image processing was based on that previously
described for the structure of the human 26S proteasome23, but taking advantage of
the new instrumentation and image recording protocol. For each exposure, the sum
of all frames captured was used to carefully screen for optimal ice thickness and
image stability by assessing the isotropic recovery of Thon rings in their power
spectra. The power spectra of the images selected for analysis had isotropic Thon
rings directly observed to 4Å or better. Using these criteria, 720 images were
selected for further processing from a total of 960 exposures recorded, all of these
acquired from a single cryo-EM grid and during a single cryo-EM session. The sum
of all frames recorded for each of the exposures selected for further processing was
also used to determine the image defocus and astigmatism parameters, using the
Tigris programme ﬁndctf, and for particle selection, which was performed
automatically in Relion24. This was followed by careful inspection of all particles
selected and manual removal of false positives and addition of false negatives,
resulting in a data set of 76,500 particles. Further image processing was done using
the sum of frames 3–10 of each exposure, corresponding to a total accumulated
electron dose of 28 e Å 2. This selection aimed at maximum specimen stability
and optimal signal-to-noise in the resulting images for accurate determination of
the particle orientations, while avoiding excessive radiation damage. In this
selection, the ﬁrst two frames captured during exposure, corresponding to the
initial accumulated dose of 5.6 e Å 2, were excluded as it is at the start of the
exposure that the most prominent beam induced particle movements are
observed25. As a consequence of our data collection protocol, for each exposure the
selection of recorded frames used for high-resolution analysis was effectively
acquired within 0.45 s. Within this short time, the individual particle images
showed negligible translational displacement and hence it was not judged necessary
to further align these frames. The phases of the resulting images were corrected for
the contrast transfer function by phase ﬂipping with the Tigris programme ﬂipctf,
using the image defocus and astigmatism parameters determined using the full
exposures as described above. Selected particle images were then extracted into
256 256 pixel boxes. A model derived from the coordinates of the bovine
constitutive apo 20S proteasome core, as ﬁtted into the 3D map of the human 26S
proteasome23 and Fourier low-pass ﬁltered to 20Å, was used as an initial reference
for single-particle analysis of the human 20S proteasome core in the apo state (data
not shown). The resulting map, again low-pass ﬁltered to 20Å, was used as a
starting reference for the analysis of the human 20S–AdaAhx3L3VS complex. The
single-particle analysis reﬁnement routine, performed using C2 symmetry,
consisted of rounds of alignment and Euler angle assignment using the programme
AP SH of the Spider software package26, 3D reconstruction and forward projection.
3D reconstructions and forward projections were performed using the locally
developed icr3d and icr3dpro programs implemented in Tigris. The 3D
reconstruction algorithm included correction for the amplitude component of the
contrast transfer function. The Tigris software package is publicly available at
sourceforge.net. The surface representations of the ﬁnal map, as determined by the
3D reconstruction algorithm without further sharpening, Fourier ﬁltering or
masking, shown in Fig. 1c,d were created with UCSF Chimera27. They were surface
rendered and colour coded according to local resolution as determined by
ResMap15.
Molecular modelling. The model of the human 20S proteasome core was built
based on the X-ray crystal structure of the mouse constitutive apo 20S proteasome
core4 using real-space reﬁnement in Coot28 and Phenix29. The model generated in
this way was checked for geometry, close contacts and bond parameters using
MolProbity14 (Supplementary Fig. 1a), with the statistics obtained consistent with


































Figure 4 | Conformations of the -L3VS moiety of AdaAhx3L3VS and
ZL3VS bound to the 20S proteasome core. (a) Structural formulae of
AdaAhx3L3VS and ZL3VS with their -L3VS moiety boxed. (b) The -L3VS
moiety of the AdaAhx3L3VS molecule (in magenta) at the human 20S
proteasome core b5 subunit active site is shown with superimposed
coordinates for ZL3VS (grey), as found in a yeast 20S proteasome core
crystallographic structure19.
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stage of model building, the scaling of the 3D map of the human 20S–AdaAhx3L3VS
complex was tested, and model building using a sampling of 1.04Å per pixel
resulted in the most favourable protein coordinate MolProbity scores, indicating
accuracy in the sampling used. Models for the individual copies of the -L3VS moiety
of the AdaAhx3L3VS molecule, at each of the 20S proteasome core active sites, were
built in using Coot. The mesh representations of the ﬁnal map showing the model of
the human 20S proteasome core (Figs 2 and 3) were created using the PyMOL
Molecular Graphics System. For these representations, the map was sharpened with
a B-factor of 50 and Fourier low-pass ﬁltered to 3.4Å.
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